CROs Poised to Benefit From Biopharma Outsourcing
Of the contract research organizations we cover, Syneos looks most attractively valued.
Our thesis for the contract research organization industry remains that continued outsourcing from biotechnology and pharmaceutical companies will drive growth for the larger global CROs that help design and conduct clinical trials. After transferring coverage of the major late-stage CROs, we are maintaining our narrow moat and stable trend ratings for Syneos Health (SYNH), PRA Health Sciences (PRAH), and Icon (ICLR). We’ve downgraded market leader IQVIA’s (IQV) moat rating to narrow from wide after reconsidering the company’s long-term competitive positioning in the clinical research and data spaces. Of these four, Syneos is most attractively valued, but we note that it’s the only one with a high uncertainty rating as a result of its high debt load.
With IQVIA’s moat downgrade, we’ve lowered our fair value estimate to $114 per share from $118. While we believe that intangible assets and switching costs underpin a narrow economic moat for IQVIA, we no longer have confidence that the company will earn excess returns for at least 20 years. Returns on invested capital were significantly diminished following the 2016 merger of Quintiles and IMS Health, and we do not have high confidence that the company will maintain its monopolistic hold on aggregated patient data for more than a decade. CROs and software companies are increasingly engaging with patient data as it begins to play an increasing role in clinical research and commercialization, and we believe improving technology and interoperability could eventually lower barriers to accessing this data.
Anna Baran does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.